{ "data": { "id": "org_national-medical-products-administration", "slug": "national-medical-products-administration", "name": "National Medical Products Administration", "short_name": "NMPA", "type": "government", "tier": 1, "homepage": "https://english.nmpa.gov.cn", "country_code": "CN", "reliability_note": null, "url": "https://statorigin.org/sources/national-medical-products-administration", "documents": [ { "title": "China approves 48 innovative drugs in 2024", "url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 6 }, { "title": "Measures facilitate approval of 48 first-in-class innovative drugs", "url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "doc_type": "press_release", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok", "statistic_count": 13 } ], "statistics": [ { "id": "stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H", "url": "https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H", "indicator": { "slug": "alzheimer-s-disease-innovative-drug-clinical-trial-approvals-multi-year-total", "name": "Alzheimer's disease innovative drug clinical trial approvals (multi-year total)", "definition": "Number of innovative drugs approved to initiate clinical trials for the treatment of Alzheimer's disease during the specified period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2024-12-31", "type": "year" }, "value": 8, "value_text": "eight", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "In the past two years, it has approved clinical trials for eight innovative drugs that could potentially treat the disease.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H", "bibtex": "@misc{nmpa2024alzheimera9av3h,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_ZJH1W89QNDGEPZ0NG0HRA9AV3H},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_N9A1J88TV8X7J63HZ4MEQ9G5C2", "url": "https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2", "indicator": { "slug": "approved-innovative-drugs-designated-as-breakthrough-therapies", "name": "Approved innovative drugs designated as breakthrough therapies", "definition": "Number of approved innovative drugs that previously received breakthrough therapy designation during development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2", "bibtex": "@misc{nmpa2024approvedq9g5c2,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_N9A1J88TV8X7J63HZ4MEQ9G5C2},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_T1T4DYFSWBGNW2SKA622VN2Y2D", "url": "https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D", "indicator": { "slug": "approved-novel-drugs-in-breakthrough-therapy-programs", "name": "Approved novel drugs in breakthrough therapy programs", "definition": "Number of approved novel drugs that participated in breakthrough therapy programs during clinical development." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 13, "value_text": "13", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D", "bibtex": "@misc{nmpa2024approvedvn2y2d,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T1T4DYFSWBGNW2SKA622VN2Y2D},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_K4TT8DNWNY5FFD4SR1X56F0PT1", "url": "https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1", "indicator": { "slug": "cumulative-drug-approval-applications-under-priority-review-annual", "name": "Cumulative drug approval applications under priority review (annual)", "definition": "Total cumulative number of drug approval applications granted priority review status since program inception." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 496, "value_text": "496", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1", "bibtex": "@misc{nmpa2024cumulative6f0pt1,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_K4TT8DNWNY5FFD4SR1X56F0PT1},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_PKSBVMH1C6K0AJ8281JPG7AGSM", "url": "https://statorigin.org/stat/stat_PKSBVMH1C6K0AJ8281JPG7AGSM", "indicator": { "slug": "drug-approval-applications-completed-under-priority-review", "name": "Drug approval applications completed under priority review", "definition": "Total number of drug approval applications completed under an expedited priority review pathway." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 110, "value_text": "110", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "\"In 2024, the administration completed 110 drug approval applications covering 74 different categories under the priority review pathway, marking a year-on-year increase of 29 percent,\" Yuan said.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_PKSBVMH1C6K0AJ8281JPG7AGSM", "bibtex": "@misc{nmpa2024drugg7agsm,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_PKSBVMH1C6K0AJ8281JPG7AGSM},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_M2CT8W1DFWZP0REVGEVMVVD25V", "url": "https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 48, "value_text": "48", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "China approved 48 first-in-class innovative drugs in 2024, covering nearly 20 therapeutic areas, including oncology, neurological disorders, endocrine diseases and anti-infective medicines, according to a report released by the National Medical Products Administration on Tuesday.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V", "bibtex": "@misc{nmpa2024firstvvd25v,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_M2CT8W1DFWZP0REVGEVMVVD25V},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_KNZB8QGH5G14C6AH9Y1T332SVW", "url": "https://statorigin.org/stat/stat_KNZB8QGH5G14C6AH9Y1T332SVW", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 48, "value_text": "48", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "China approved 48 first-in-class innovative drugs, as well as a significant number of medications for pediatric and rare diseases, thanks to measures aimed at enhancing review efficiency and accelerating patient access to novel therapies, according to a report released on Tuesday by the National Medical Products Administration.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_KNZB8QGH5G14C6AH9Y1T332SVW", "bibtex": "@misc{nmpa2024first332svw,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_KNZB8QGH5G14C6AH9Y1T332SVW},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QQAK8A3S9PYQF02R7JY3ZW0M14", "url": "https://statorigin.org/stat/stat_QQAK8A3S9PYQF02R7JY3ZW0M14", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 40, "value_text": "40", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "The number was the highest in the past five years, compared with 40 in 2023 and 21 in 2022.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2023). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_QQAK8A3S9PYQF02R7JY3ZW0M14", "bibtex": "@misc{nmpa2023firstzw0m14,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QQAK8A3S9PYQF02R7JY3ZW0M14},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_V2PVD0MBZF95WVXXN20DWVCP41", "url": "https://statorigin.org/stat/stat_V2PVD0MBZF95WVXXN20DWVCP41", "indicator": { "slug": "first-in-class-drug-approvals", "name": "First-in-class drug approvals", "definition": "Number of approved therapeutic drugs featuring a novel biological mechanism of action." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2022-01-01", "end": "2022-12-31", "type": "year" }, "value": 21, "value_text": "21", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "The number was the highest in the past five years, compared with 40 in 2023 and 21 in 2022.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2022). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_V2PVD0MBZF95WVXXN20DWVCP41", "bibtex": "@misc{nmpa2022firstwvcp41,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2022},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_V2PVD0MBZF95WVXXN20DWVCP41},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_R0YVQBK50ZFQ437EEKJ7V1NH17", "url": "https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17", "indicator": { "slug": "innovative-drugs-approved-via-priority-review-pathway", "name": "Innovative drugs approved via priority review pathway", "definition": "Number of innovative drugs approved for marketing through expedited priority review procedures." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 17, "value_text": "17", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17", "bibtex": "@misc{nmpa2024innovativev1nh17,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_R0YVQBK50ZFQ437EEKJ7V1NH17},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_2VV0A98K89ACW40MG9XWRJ02NZ", "url": "https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ", "indicator": { "slug": "innovative-drugs-granted-conditional-market-approval", "name": "Innovative drugs granted conditional market approval", "definition": "Number of innovative pharmaceuticals granted conditional marketing authorization based on surrogate or preliminary clinical endpoints." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 11, "value_text": "11", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Among them, 17 received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials, according to the report from the administration's drug evaluation center.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ", "bibtex": "@misc{nmpa2024innovativerj02nz,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_2VV0A98K89ACW40MG9XWRJ02NZ},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7HAGBREDP4PN54PGTD9JEWGTR4", "url": "https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4", "indicator": { "slug": "novel-drug-approvals-via-priority-review-pathway", "name": "Novel drug approvals via priority review pathway", "definition": "Number of novel drugs granted market approval through a priority review regulatory pathway." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 17, "value_text": "17", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4", "bibtex": "@misc{nmpa2024novelewgtr4,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7HAGBREDP4PN54PGTD9JEWGTR4},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_H0T71ZXTRQ0KB3D90ZEVZX3D5J", "url": "https://statorigin.org/stat/stat_H0T71ZXTRQ0KB3D90ZEVZX3D5J", "indicator": { "slug": "novel-drugs-granted-conditional-market-approval", "name": "Novel drugs granted conditional market approval", "definition": "Number of novel drugs granted conditional market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 11, "value_text": "11", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "The report stated that 17 among the 48 novel drugs received market approval through a priority review pathway, 11 gained conditional market approval and 13 were included in breakthrough therapy programs during clinical trials.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_H0T71ZXTRQ0KB3D90ZEVZX3D5J", "bibtex": "@misc{nmpa2024novelzx3d5j,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H0T71ZXTRQ0KB3D90ZEVZX3D5J},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1XPXZWT1KN4DBS2AMDJEYDN0T7", "url": "https://statorigin.org/stat/stat_1XPXZWT1KN4DBS2AMDJEYDN0T7", "indicator": { "slug": "pediatric-medicine-approvals", "name": "Pediatric medicine approvals", "definition": "Number of pediatric medicines granted market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 106, "value_text": "106", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "In addition, the nation also approved 55 rare disease medicines and 106 pediatric medicines.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_1XPXZWT1KN4DBS2AMDJEYDN0T7", "bibtex": "@misc{nmpa2024pediatricydn0t7,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1XPXZWT1KN4DBS2AMDJEYDN0T7},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_20PWA75BYWGZH9KYZRBT7ECBA6", "url": "https://statorigin.org/stat/stat_20PWA75BYWGZH9KYZRBT7ECBA6", "indicator": { "slug": "pediatric-medicine-approvals", "name": "Pediatric medicine approvals", "definition": "Number of pediatric medicines granted market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 106, "value_text": "106", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "In addition, China approved 106 pediatric medicines, and 35 medications were granted expanded pediatric indications, which is expected to help alleviate the shortage of pediatric medication options, the report said.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_20PWA75BYWGZH9KYZRBT7ECBA6", "bibtex": "@misc{nmpa2024pediatric7ecba6,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_20PWA75BYWGZH9KYZRBT7ECBA6},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_3TKWH7JG37V05XGH480YBB37QS", "url": "https://statorigin.org/stat/stat_3TKWH7JG37V05XGH480YBB37QS", "indicator": { "slug": "priority-review-drug-approval-applications-completed-growth-rate", "name": "Priority review drug approval applications completed growth rate", "definition": "Year-on-year percentage change in completed priority review drug approval applications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 29, "value_text": "29 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "\"In 2024, the administration completed 110 drug approval applications covering 74 different categories under the priority review pathway, marking a year-on-year increase of 29 percent,\" Yuan said.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_3TKWH7JG37V05XGH480YBB37QS", "bibtex": "@misc{nmpa2024prioritybb37qs,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_3TKWH7JG37V05XGH480YBB37QS},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1YQ3S0N101YBKZ8R9REBD05AKY", "url": "https://statorigin.org/stat/stat_1YQ3S0N101YBKZ8R9REBD05AKY", "indicator": { "slug": "rare-disease-medicine-approvals", "name": "Rare disease medicine approvals", "definition": "Number of rare disease medicines granted market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 55, "value_text": "55", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "China approves 48 innovative drugs in 2024", "document_url": "https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm", "document_type": "press_release", "locator": "China approves 48 innovative drugs in 2024", "quote": "In addition, the nation also approved 55 rare disease medicines and 106 pediatric medicines.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). China approves 48 innovative drugs in 2024. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/19/c_1079532.htm. Via StatOrigin, https://statorigin.org/stat/stat_1YQ3S0N101YBKZ8R9REBD05AKY", "bibtex": "@misc{nmpa2024rared05aky,\n author = {{National Medical Products Administration}},\n title = {China approves 48 innovative drugs in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1YQ3S0N101YBKZ8R9REBD05AKY},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/19/c\\_1079532.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_F9HZ34542T02XSNMYPKMMW3KR4", "url": "https://statorigin.org/stat/stat_F9HZ34542T02XSNMYPKMMW3KR4", "indicator": { "slug": "rare-disease-medicine-approvals", "name": "Rare disease medicine approvals", "definition": "Number of rare disease medicines granted market approval." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 55, "value_text": "55", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Furthermore, 55 rare disease medicines were authorized for market last year.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_F9HZ34542T02XSNMYPKMMW3KR4", "bibtex": "@misc{nmpa2024raremw3kr4,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F9HZ34542T02XSNMYPKMMW3KR4},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_1VR49PJRJ0WBBE1PHP4ETZ5YY8", "url": "https://statorigin.org/stat/stat_1VR49PJRJ0WBBE1PHP4ETZ5YY8", "indicator": { "slug": "share-of-priority-review-drug-approval-applications-treating-cancer-annual", "name": "Share of priority review drug approval applications treating cancer (annual)", "definition": "Percentage share of priority review drug approval applications targeting oncology indications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "CN", "name": "China", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 42.54, "value_text": "42.54 percent", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "National Medical Products Administration", "org_short_name": "NMPA", "org_url": "https://english.nmpa.gov.cn", "org_tier": 1, "document_title": "Measures facilitate approval of 48 first-in-class innovative drugs", "document_url": "https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm", "document_type": "press_release", "locator": "Measures facilitate approval of 48 first-in-class innovative drugs", "quote": "Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "National Medical Products Administration. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.nmpa.gov.cn/2025-03/21/c_1080286.htm. Via StatOrigin, https://statorigin.org/stat/stat_1VR49PJRJ0WBBE1PHP4ETZ5YY8", "bibtex": "@misc{nmpa2024sharetz5yy8,\n author = {{National Medical Products Administration}},\n title = {Measures facilitate approval of 48 first-in-class innovative drugs},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_1VR49PJRJ0WBBE1PHP4ETZ5YY8},\n note = {Original source: https://english.nmpa.gov.cn/2025-03/21/c\\_1080286.htm. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ] }, "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 19, "note": "Statistics are capped at 100 per request. Use /statistics?source_org=national-medical-products-administration with a cursor to page through everything." } }